BTIG Reiterates Buy Rating on Natera, Inc. with $275 Target
BTIG maintains its buy rating on Natera, Inc. with a $275 price target, a 5% upside from the current price.
Key Points
- BTIG reiterated its buy rating on Natera, Inc. (NTRA) with a price target of $275 on June 24, 2026.
- BTIG's $275 price target implies 5% upside from Natera, Inc.'s ($NTRA) current $261.91 share price.
- Shares of Natera traded near $247.66 on Wednesday, with a market cap of $32.77 billion and forward P/E of -1097.994.
- Natera insiders have been selling shares under Rule 10b5-1 plans, including Executive Chairman Matthew Rabinowitz.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG has reiterated its buy rating on Natera, Inc. (NasdaqGS: NTRA) with a price target of $275. This announcement came on Wednesday, June 24, 2026, as analyst Mark Massaro expressed continued confidence in the company's potential. Shares of Natera traded near $247.66 on the same day.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Natera, Inc. Stock Down 19.7%
Natera, Inc. has a market cap of approximately $32.77 billion. The company's stock has been volatile, with a 52-week low of $131.81 and a high of $256.36. It has a beta of 1.544, indicating higher volatility compared to the market. The forward P/E ratio is not meaningful as the company is not currently profitable, reporting a negative EPS of -1.62. Natera's 50-day moving average is $207.88, while the 200-day moving average stands at $206.57.
$NTRA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its latest earnings report, Natera posted revenue of $2.50 billion, reflecting a growth rate of 38.8%. However, the company reported a net margin of -9.05% and a return on equity of -15.02%, indicating ongoing challenges in achieving profitability. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Natera, Inc.
Several insiders at Natera have been selling shares recently, all under pre-arranged Rule 10b5-1 trading plans. Notably, Executive Chairman Matthew Rabinowitz sold two blocks of 50,000 shares each on June 15 and June 12, at prices around $214.91 and $214.03, respectively. Other insiders, including Sheena Jonathan and Rowan Chapman, have also sold shares in June.
Analysts Set New Price Targets
On June 24, 2026, BTIG maintained its buy rating on Natera with a $275 price target. Barclays also maintained a buy rating with a $260 target on the same day. Earlier in June, RBC Capital reinstated its buy rating with a $275 target, while Goldman Sachs initiated coverage with a hold rating and a $245 target.
About Natera, Inc.
Natera, Inc., based in Austin, Texas, is a healthcare company specializing in diagnostics and research. It offers a range of molecular testing services, including the Signatera test for cancer monitoring and the Panorama non-invasive prenatal test. Led by CEO Steven Leonard Chapman, Natera employs over 6,000 people and partners with various laboratories and pharmaceutical companies to deliver its testing services globally.
Bottom Line
BTIG's reiterated buy rating on Natera, Inc. underscores ongoing confidence in the company's growth prospects, despite its current lack of profitability. Investors keep a close eye on analyst ratings like this to gauge market sentiment and potential future performance. It's important to remember that these ratings reflect backward-looking assessments and may not indicate current market conditions.
Get Natera, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NTRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.